|
(ÁÖ)½º¸¶Æ®¿¡ÀÌÄ¡¾Ë |
»ù¹°ÇÐ,¹ÙÀÌ¿ÀÇÕ¼º¿¬±¸,°³¹ß
°æ±â ¼ö¿ø½Ã ¿µÅ뱸 | ´ëÇÐ(4³â) ÀçÇÐ |
¿¬±¸/¿¬±¸±âȹ |
2³â¡è |
ä¿ë½Ã |
11.05 |
|
|
µå¸²¼Ö·ç¼Ç |
»óÀå»ç ÀÇ·á±â±â ¿¬±¸¼Ò Analog HW,µðÁöÅ» H/W,½Åȣó¸®,¿µ
¼¿ï °³²±¸ | ´ëÇÐ(4³â) ÀçÇÐ |
°³¹ß/RA/´ë°ü |
2³â¡è |
ä¿ë½Ã |
03.06 |
|
|
¿¡À̽ºÆÄÆ®³Ê½º |
¿Ü±¹°è ¸¶ÄÉÆÃȸ»ç Outcomes research team
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
02.18 |
|
|
¿¡À̽ºÆÄÆ®³Ê½º |
¿Ü±¹°è ÀǾà Àü¹® ¸¶ÄÉÆà ¸®¼Ä¡ ȸ»ç ÆÀÀå±Þ ¸ðÁý
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
04.30 |
|
|
OOȍ |
±¹³» Áß°ß Á¦¾à»ç Á¦Á¦¿¬±¸¼Ò °æ·ÂÁ÷ ¸ðÁý
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) ÀçÇÐ |
¿¬±¸/¿¬±¸±âȹ |
3³â¡è |
ä¿ë½Ã |
06.14 |
|
|
JC Econet |
ÇؿܸÞÀÌÀúÁ¦¾àȸ»ç Health Science Associate
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
5³â¡è |
ä¿ë½Ã |
05.24 |
|
|
Ä¿¸®¾îHR |
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
¿¬±¸/¿¬±¸±âȹ |
1³â¡è |
ä¿ë½Ã |
12.03 |
|
|
(ÁÖ)¾ËÆĸ޵å |
ÃÊÀ½ÆÄÁø´Ü±â¹× Áø´ÜÀåºñ ¿µ¾÷ °æ·ÂÁ÷ ¸ðÁý
°æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
»ó½Ãä¿ë |
09.25 |
|
|
DKSH Korea Ltd. |
Rx/Pharma Marketing Specialist (Àü¹®ÀǾàÇ° ¸¶ÄÉÆÃ)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) ÀçÇÐ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
3³â¡è |
ä¿ë½Ã |
06.13 |
|
|
PRA Health Sciences |
[PRA Health Sciences] CRA I, II, III, Drug Safety Associ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
06.28 |
|
|
YGÄÄÆÛ´Ï |
Á¦¾à¿µ¾÷ ½ÅÀÔ ¸ðÁý
ºÎ»ê ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
½ÅÀÔ |
ä¿ë½Ã |
06.29 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Çѱ¹MSD CRA 0¸í ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
05.10 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] QC Project management
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) ÀçÇÐ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
5³â¡è |
ä¿ë½Ã |
09.19 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] QC Project management
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) ÀçÇÐ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
5³â¡è |
ä¿ë½Ã |
09.09 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Sales Team Leader
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) ÀçÇÐ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
7³â¡è |
ä¿ë½Ã |
12.04 |
|